HealthyStock
Site Search

Facts
Trazodone
Celexa
Lexapro
Prozac
Paxil
Zoloft
Wellbutrin XL
Bupropion
Cymbalta
Effexor
Buspar
Remeron
Amitriptyline
Information
Trazodone
Celexa (Citalopram)
Cymbalta
Escitalopram
Paroxetine
Fluoxetine
Zoloft (Sertraline)
Effexor XR (Venlafaxine)

Lexapro (Escitalopram)


  • Generic name: escitalopram oxalate
  • Brand/Trade names: Lexapro
  • Pharmacologic category: Selective serotonin reuptake inhibitor, Antidepressant
  • FDA approved: August 14, 2002
  • Manufacturer: Forest Pharmaceuticals, Inc.
  • Habit forming? No
  • Pregnancy risk factor: C
Medical Uses

Lexapro (Escitalopram Oxalate), the S-enantiomer of RS-citalopram and a highly selective SSRI, is an effective antidepressant in the treatment of Major depressive disorder. It has a favourable tolerability profile, and appears to have a rapid onset of therapeutic effect. Modelled pharmacoeconomic analyses suggest that it may be a cost-effective alternative to citalopram, fluoxetine, and sertraline. Overall, clinical and pharmacoeconomic data support the use of escitalopram as first-line therapy for depression [1].

The most common side effects with Lexapro are nausea, insomnia, ejaculation disorder, somnolence, increased sweating, fatigue, decreased libido, and anorgasmia.

Pharmacological characteristics
  • Absorption: Absorption is expected to be almost complete and independent of food intake.
  • Metabolism: Hepatic via CYP2C19 and 3A4 to an active metabolite, S-desmethylcitalopram (S-DCT; 1/7 the activity); S-DCT is metabolized to S-didesmethylcitalopram (S-DDCT; active; 1/27 the activity) via CYP2D6
  • Excretion: Urine (Escitalopram: 8%; S-DCT: 10%)
  • Elimination half-life: Escitalopram: 27-32 hours; S-desmethylcitalopram: 59 hours
Advantages
  • most selective of all SSRIs
  • favorable side-effect profile
  • more effective than citalopram and some other SSRIs in the treatment of major depression
  • works quickly - more rapid onset of effect than other SSRIs, improvements are noted at week 1 or 2 [2]
  • fewer problems with discontinuation than either paroxetine and venlafaxine [3]
  • superior efficacy in comparison with conventional SSRIs, particularly in the treatment of more severe depression
  • relatively low incidence of sexual side effects and weight gain
Concerns
  • expensive
Unlabeled Uses
  • panic disorder [4]
  • social anxiety disorder [5]
  • posttraumatic stress disorder
  • premenstrual dysphoric disorder [6]
  • bipolar disorder
Mechanism of Action

Escitalopram is the S-enantiomer of the racemic derivative citalopram, which selectively inhibits the reuptake of serotonin with little to no effect on norepinephrine or dopamine reuptake. It has no or very low affinity for 5-HT1-7, alpha- and beta-adrenergic, D1-5, H1-3, M1-5, and benzodiazepine receptors. It does not bind or has low affinity for Na+, K+, Cl-, and Ca++ ion channels.

Discussions Boards & Forums
References
  • Lexapro official website
  • Escitalopram on MedlinePlus
  • 1. Croom KF, Plosker GL. Escitalopram: a pharmacoeconomic review of its use in depression. Pharmacoeconomics. 2003;21(16):1185-209.
  • 2. Wade A, Friis Andersen H. The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin. 2006 Nov;22(11):2101-10. PubMed
  • 3. Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol. 2007 Feb;10(1):73-84. PubMed
  • 4. 13. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003 Nov;64(11):1322-7. PubMed
  • 5. Stein DJ, Kasper S, Andersen EW, Nil R, Lader M. Escitalopram in the treatment of social anxiety disorder: analysis of efficacy for different clinical subgroups and symptom dimensions. Depress Anxiety. 2004;20(4):175-81.
  • 6. 15. Freeman EW, Sondheimer SJ, Sammel MD, Ferdousi T, Lin H. A preliminary study of luteal phase versus symptom-onset dosing with escitalopram for premenstrual dysphoric disorder. J Clin Psychiatry. 2005 Jun;66(6):769-73. PubMed

Last modified: August, 2010

Interesting facts

lexapro
Forest Pharmaceuticals
  • Lexapro is the newest and most selective of the selective serotonin reuptake inhibitors approved by the FDA for the treatment of depression.
  • It is a cleaner, improved version of Celexa.
  • In fact, 47% of patients who did not respond to Celexa treatment responded to treatment with Lexapro.
  • This medication seems to offer a less complicated pharmacokinetic profile and better tolerability.

Contact Us

Copyright © 2009 HealthyStock.net. All rights reserved.
All information on HealthyStock.net is intended for general knowledge only.
For medical advice consult with your physician.